Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

110.20EUR
18 Aug 2017
Change (% chg)

€0.15 (+0.14%)
Prev Close
€110.05
Open
€109.80
Day's High
€110.55
Day's Low
€108.30
Volume
92,651
Avg. Vol
174,239
52-wk High
€129.85
52-wk Low
€57.36

IPN.PA

Chart for IPN.PA

About

Ipsen SA is a France-based pharmaceutical company. The Company is focused on various therapeutic areas, including onocology, endocrinology, neurosciences and primary care. Its onocology portfolio includes Somatuline, Decapeptyl, Hexvix and Cabometyx. Its endocrinology portfolio includes Increlex and NutropinAq. Its primary care... (more)

Overall

Beta: 0.79
Market Cap(Mil.): €9,216.90
Shares Outstanding(Mil.): 83.64
Dividend: 0.85
Yield (%): 0.77

Financials

  IPN.PA Industry Sector
P/E (TTM): 42.43 31.45 32.56
EPS (TTM): 2.60 -- --
ROI: 11.19 15.33 14.89
ROE: 16.34 16.35 16.13

Pharma group Ipsen raises margin target after strong H1

July 27 French pharmaceutical group Ipsen raised its annual margin target on Thursday on the back of a strong first half, boosted by its core speciality care business which includes oncology and endocrinology products.

Jul 27 2017

BRIEF-Ipsen delivers H1 sales growth of 18.8%, upgrades its FY 2017 guidance

* IPSEN DELIVERS STRONG SALES GROWTH OF 18.8% IN THE FIRST HALF OF 2017 AND UPGRADES ITS GUIDANCE FOR FULL YEAR 2017

Jul 27 2017

BRIEF-Ipsen receives positive CHMP opinion for approval of Cermelo

* Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy Source text for Eikon: Further company coverage:

Jul 21 2017

BRIEF-Ipsen receives positive CHMP opinion for approval of Xermelo‍​

* POSITIVE OPINION BASED ON RESULTS OF TWO RANDOMIZED PHASE 3 TRIALS, TELESTAR AND TELECAST

Jul 21 2017

BRIEF-Ipsen Somatuline Autogel 120 mg receives Japanese approval for new indication for treatment of gastro-entero-pancreatic neuroendocrine tumors

* IPSEN: SOMATULINE AUTOGEL 120 MG RECEIVES JAPANESE APPROVAL FOR A NEW INDICATION FOR THE TREATMENT OF GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 03 2017

BRIEF-Ipsen announces Dysport co-promotion agreement with Saol

* Ipsen announces Dysport co-promotion agreement with Saol Therapeutics to expand commercial reach in the united states

Jun 30 2017

BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

* IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA

Jun 19 2017

BRIEF-Ipsen announces FDA approval of Dysport(Abobotulinumtoxina) for treatment of lower limb spasticity in adults

* IPSEN ANNOUNCES FDA APPROVAL OF DYSPORT (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 16 2017

Ipsen CFO says group does not plan any large share buyback operation

PARIS, June 2 French pharmaceutical group Ipsen does not plan any large share buyback operation for the moment, chief financial officer Aymeric Le Chatelier said on Friday.

Jun 02 2017

BRIEF-Ipsen sees 2020 sales to exceed 2.5 billion euros

* IPSEN PRESENTS ITS NEW STRATEGY AND IMPROVED 2020 FINANCIAL TARGETS

May 11 2017

Earnings vs. Estimates